CME/CE

1-16 of 45

• 

  RestartResume

  Ongoing Trials in Oral Targeted Strategies in Breast Cancer

  RestartResume

  Ongoing Trials in Oral Targeted Strategies in Breast Cancer

  MinuteCE®

  Ongoing Trials in Oral Targeted Strategies in Breast Cancer

  Aditya Bardia, MD, MPH, FASCO

  0.50 program credits

  • 

    

    Aditya Bardia, MD, MPH, FASCO

  0.50 program credits

• 

  RestartResume

  SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer

  RestartResume

  SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer

  MinuteCE®

  SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer

  Erica L. Mayer, MD, MPH

  0.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  0.50 program credits

• 

  RestartResume

  ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer

  RestartResume

  ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer

  MinuteCE®

  ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer

  Aditya Bardia, MD, MPH, FASCO

  0.50 program credits

  • 

    

    Aditya Bardia, MD, MPH, FASCO

  0.50 program credits

• 

  MinuteCE®

  Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer

  Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH

  0.50 credits 3 episodes

  • 

    

    Aditya Bardia, MD, MPH, FASCO

  • 

    

    Erica L. Mayer, MD, MPH

  0.50 credits 3 episodes

• 

  CME/CE In-Person Event

  22nd Annual Women’s Health Annual Visit (WHAV)

  Multiple dates & locations available

  6.00 credits

• 

  RestartResume

  Minimal By Design: Define MSE Endpoints

  RestartResume

  Minimal By Design: Define MSE Endpoints

  MinuteCE®

  Minimal By Design: Define MSE Endpoints

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  The 2-Point Signal: Apply ≥2-Point Rule

  RestartResume

  The 2-Point Signal: Apply ≥2-Point Rule

  MinuteCE®

  The 2-Point Signal: Apply ≥2-Point Rule

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  Shared Goals, Shared Gains: Align With Patient Preferences

  RestartResume

  Shared Goals, Shared Gains: Align With Patient Preferences

  MinuteCE®

  Shared Goals, Shared Gains: Align With Patient Preferences

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  FcRn: Same Class, Different Paths—Spot Agent Differentiators

  RestartResume

  FcRn: Same Class, Different Paths—Spot Agent Differentiators

  MinuteCE®

  FcRn: Same Class, Different Paths—Spot Agent Differentiators

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  Turning Flares Into Function: Flag Uncontrolled Disease

  RestartResume

  Turning Flares Into Function: Flag Uncontrolled Disease

  MinuteCE®

  Turning Flares Into Function: Flag Uncontrolled Disease

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  Target Locked in gMG: Why T2T Matters

  RestartResume

  Target Locked in gMG: Why T2T Matters

  MinuteCE®

  Target Locked in gMG: Why T2T Matters

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  The IgG Clock: Redose Using IgG Kinetics

  RestartResume

  The IgG Clock: Redose Using IgG Kinetics

  MinuteCE®

  The IgG Clock: Redose Using IgG Kinetics

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  RestartResume

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  MinuteCE®

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  Christyn Edmundson, MD

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  1.00 program credit

• 

  MinuteCE®

  Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 credit 10 episodes

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 credit 10 episodes

• 

  RestartResume

  Escalate With Intention: Stepwise, Target-Anchored Moves

  RestartResume

  Escalate With Intention: Stepwise, Target-Anchored Moves

  MinuteCE®

  Escalate With Intention: Stepwise, Target-Anchored Moves

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  When to Begin FcRn: Initiation Criteria, Key Evidence

  RestartResume

  When to Begin FcRn: Initiation Criteria, Key Evidence

  MinuteCE®

  When to Begin FcRn: Initiation Criteria, Key Evidence

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• Prev
• 1
• 2
• 3
• Next